title: Refill adherence of antihyperglycaemic drugs related to glucose control (HbA1c) in patients with type 2 diabetes.
abstract: The aim of this study was to examine a potential association between: (1) refill adherence to antihyperglycaemic drugs and glucose control, and (2) adherence to antihyperglycaemic and cardiovascular drugs for the same patients. Consecutive patients with type 2 diabetes at six Swedish health centres were included. Refill adherence was determined from repeat prescriptions. Satisfactory refill adherence was defined as the percentage of the patients with refills covering > or =80% of the prescribed treatment time. A total of 994 prescriptions were collected from 422 patients, 346 patients had antihyperglycaemic drugs (mean HbA(1c )6.5%) and 76 were on diet and exercise but not on drugs (mean HbA(1c )6.2%) (P = 0.0098). A total of 257 patients (74%) had satisfactory refill adherence. Mean HbA(1c) for the adherent patients was 6.5% and for the non-adherent patients 6.8% (P = 0.025). For patients on insulin only, 69% had satisfactory refill adherence with mean HbA(1c) 6.6% compared to 7.3% (P = 0.005) for the non-adherent patients. Ninety-two percent of the patients with satisfactory refill adherence to antihyperglycaemic agents were also adherent to cardiovascular drugs compared to 62% among those who were non-adherent to antihyperglycaemic drugs (P < 0.001). Patients with satisfactory refill adherence have lower HbA(1c)-levels and higher adherence to cardiovascular drugs than non-adherent patients.
authors.affiliation: Hentorps Vårdcentral, Skövde, Sweden.
authors.forename: Lena
authors.initials: L
authors.lastname: Kindmalm
authors.forename: Arne
authors.initials: A
authors.lastname: Melander
authors.forename: J Lars G
authors.initials: JL
authors.lastname: Nilsson
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000523:psychology; D011307:Drug Prescriptions; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D010349:Patient Compliance